Navigation Links
NEBA Health earns patent for integration of NEBA biomarker with clinician's ADHD evaluation
Date:8/15/2013

BOULDER, Colo., Aug. 15, 2013 /PRNewswire/ -- NEBA Health, LLC announces today that Dr. Steven M. Snyder, Research and Development Vice President, has earned US Patent 8,509,884.  The patent protects a key aspect of the NEBA system:  integrating the biomarker with a clinician's workup for ADHD.  "NEBA is not a standalone diagnostic," said Dr. Snyder.  "After the clinician's ADHD evaluation, NEBA helps them determine if the symptoms are due to ADHD or if further testing is warranted."  

"Integrating the NEBA biomarker with a clinician's initial diagnostic impression can bring a clinician's diagnosis more in line with that of multidisciplinary team," said Dr. Snyder.  Research supports that compared to a clinician alone, a multidisciplinary team is better able to determine if ADHD-like symptoms are accounted for by another condition. 

In order to diagnose ADHD, a clinician not only observes criteria regarding behavioral symptoms and impairment, but also must determine whether symptoms would be better accounted for by another condition.  Because ADHD shares symptoms with other disorders, the diagnosis may be difficult.  According to the US Center for Disease Control and Prevention (CDC), 9.5% of all children and adolescents have an ADHD diagnosis.  The ADHD diagnosis rate is increasing.  CDC states that rates of ADHD diagnosis increased an average of 3% per year from 1997 to 2006 and an average of 5.5% per year from 2003 to 2007.

"In their ADHD evaluation, clinicians may be challenged in the current medical environment to determine the primary diagnosis when overlapping symptoms are present," said Howard Merry, President of NEBA Health.  "We are delighted that the USPTO has awarded Dr. Snyder the patent.  It covers NEBA's core technology, and it's another validation point for the 7 years we spent developing and validating NEBA." 

About NEBA Health

NEBA Health has developed the first FDA approved medical device based on brain waves to help assess ADHD.  The device, NEBA, is cleared in the USA (K112711), CE marked, and Health Canada licensed.  To our knowledge, the NEBA FDA validation study is the largest ADHD diagnostic study of this nature ever conducted (275 subjects at 13 clinical sites).  We have ongoing work in ADHD, depression, and dementia.  Our technologies are NIEAAs (Neuropsychiatric Interpretive EEG-based Assessment Aids).  NEBA Health is privately held.


'/>"/>
SOURCE NEBA Health, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First students at new College of Pharmacy to begin classes next week at UNT Health Science Center
2. mHealth Identified as Critical Strategy in Medication Adherence Programs
3. iSALUS Healthcare Expands Revenue Cycle Management Services with Billnet Solutions
4. Natus Neurology Incorporated Receives 510(k) & Health Canada Clearance And Launches New Electrodiagnostic System In U.S. & Canada
5. Millennium HealthCare Inc. Featured in Forbes
6. Wolters Kluwer Health Launches Nursing Drug Handbook Specialty Apps
7. PinnacleHealth, Meridian Health Select Perioperative IT from Surgical Information Systems
8. Hospira to Present at the Morgan Stanley Global Healthcare Conference
9. Chinas Strong Economic Growth and Healthcare Investments Generate Success for CPhI
10. Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions
11. Real Time Location Systems (RTLS) Market in Healthcare Industry 2011 - 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
(Date:7/6/2017)... CINCINNATI , July 6, 2017 ThriveRx, the nutrition division ... and their families to thrive on nutrition support. To celebrate ... The new site has a fresh new look with improved organization to ... ... ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... , ... July 21, 2017 , ... Hospital M&A activity ... HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the second quarter, ... and up 15% from the 20 announced deals in the year-ago second quarter. Only ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... anterior cruciate ligament (ACL) offer patients improved quality of life five years after ... Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients ...
Breaking Medicine News(10 mins):